© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Experts in breast cancer review clinical cases, discuss individualized treatment options and key clinical trials.
March 30th 2021
The experts discuss a case presentation of a 63-year-old woman with relapsed HER2+ metastatic breast cancer and discuss rate of relapse in this patient population.
Experts discuss the treatment considerations for HER2+ metastatic breast cancer and provide an overview of the DESTINY-Breast01 trial.
The experts have a detailed conversation on the HER2CLIMB trial, including third-line treatment options and the importance of having a detailed and balanced conversation with patients.
The panelists discuss clinical experience with the HER2CLIMB regimen, including main adverse effects.
The experts present and discuss a case of a patient with relapsed HER2+ metastatic breast cancer with stable brain metastases.
The experts discuss data from clinical trials of metastatic breast cancer with brain involvement.
Key opinion leaders consider later-lines of therapy in metastatic breast cancer with lung and brain involvement.
A panel of experts review the tucatinib regimen including adverse effects to keep an eye on.
April 29th 2021
Presentation and considerations for relapsed HER2+ metastatic breast cancer with progressing brain metastases.
Experts have a detailed conversation on the NALA trial of neratinib and capecitabine for HER2+ metastatic breast cancer.